Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled DMT in Healthy Adults
NCT05573568Phase 1Completed
- Sponsor
- Biomind Labs
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMND01 in treatment-resistant depression (TRD) (5 arms), sponsored by Biomind Labs. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 month, Blood Pressure at 2 hours and 3 more. Started Jun 2022; status: completed.
02
Drugs
BMND01
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05573568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573568.